No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Imfinzi (durvalumab) is a monoclonal antibody drug used to treat certain types of non-small cell lung cancer (NSCLC). It is used in combination with other drugs to treat patients with locally advanced or metastatic NSCLC who have not received prior treatment. Imfinzi works by blocking the action of a protein called PD-L1, which helps cancer cells to evade the body's immune system. Imfinzi is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and is currently being studied in clinical trials for other types of cancer.
The Imfinzi market is highly competitive, with several major pharmaceutical companies developing and marketing drugs for the treatment of NSCLC. These include AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, and Roche. Other companies, such as AbbVie, Amgen, and Novartis, are also developing drugs for the treatment of NSCLC. Show Less Read more
